Tactile Systems Technology, Inc. (TCMD) SEC Filings & Earnings Calls

Airway clearance product line revenue declined 7% due to temporary inventory management dynamics from next-gen AffloVest launch; guidance reflects more conservative view of ordering patterns.

“decrease of $0.9 million, or 7%, in sales of the airway clearance product line, due to temporary inventory management dynamics ... revised revenue outlook reflects ... more conservative view of airway clearance product line ordering patterns” · word for word

Airway clearance revenue volatility

“The decrease in the airway clearance product line revenue for the three months ended June 30, 2026 was primarily driven by inventory timing dynamics among a few large DME providers.” · word for word

Seasonality risk

“In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products.” · word for word

Dependence on third-party manufacturers

“We rely on third-party contract manufacturers for the sourcing of parts, the assembly of our controllers and the manufacturing of the garments used with our systems.” · word for word

Minimum purchase obligations and marketing commitments may create financial exposure if adoption is slow.

“Company also committed to certain minimum purchase obligations and marketing and sales promotion.” · word for word

Dependence on reimbursement from third-party payers; regulatory changes could impact.

“Company’s ability to obtain reimbursement from third-party payers for its products” · word for word

Inflation and economic conditions could affect operations.

“adverse economic conditions, including inflation, ris” · word for word

Seasonality Risk

“In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products.” · word for word

Integration Risk from LymphaTech Acquisition

“a $0.8 million increase in acquisition and integration costs related to the LymphaTech acquisition” · word for word

Reimbursement risk

“Overseeing our compliance with health care reimbursement requirements and the structure, operation and efficacy of our reimbursement function” · word for word

Regulatory compliance risk

“Assisting the Board of Directors in overseeing our regulatory compliance activities” · word for word

Medicare Coverage and Prior Authorization Risk

“On November 14, 2024 the LCD for PCDs was retired... beginning April 13, 2026, CMS will require prior authorization requests (“PARs”) for pneumatic compression devices... could result in increased claim denials, delays in shipments.” · word for word

Concentration Risk on Lymphedema Products

“Our lymphedema products accounted for 84% and 89% of our revenue for the years ended December 31, 2025 and 2024, respectively.” · word for word

Single-Source Supplier Risk

“We utilize third-party, single-source suppliers for some components and materials used in our products, and the loss of any of these suppliers could have an adverse impact on our business.” · word for word

GLP-1 Drug Impact on Addressable Market

“changes in underlying causes or risk factors for diseases that our products treat, such as the impact of GLP-1 drugs on obesity, could impact our estimates of the total addressable market.” · word for word

Seasonality in commercial insurance

“In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products.” · word for word